Zoznam všetkých zadávateľov
Zobrazuji zprávy od zadavatele: Merck
Nalezeno zpráv: 41
Merck to Showcase New Data Across MS Portfolio at EAN 2019
Zadavatel: Merck
Merck Pioneers New Efforts to See MS From the Inside Out
Zadavatel: Merck
Positive Phase II Data Further Highlights Clinical Proof of Concept for Evobrutinib, First Oral Bruton ?s Tyrosine Kinase (BTK) Inhibitor to Report Positive Phase II Clinical Results in MS
Zadavatel: Merck
Merck to Present New Data on Mavenclad®, Rebif® and the Investigational Therapy Evobrutinib at the AAN Annual Meeting 2019
Zadavatel: Merck
FDA Approves MAVENCLAD® (Cladribine) Tablets as First and Only Short-Course Oral Treatment for Relapsing-Remitting and Active Secondary Progressive Multiple Sclerosis
Zadavatel: Merck
MAVENCLAD® (Cladribine Tablets) Approved As The First Short-Course Oral Treatment for Relapsing Remitting Multiple Sclerosis in Switzerland.
Zadavatel: Merck
World MS Day 2018: Call for Greater Curiosity to Drive Understanding of the Disease and Future Innovation
Zadavatel: Merck
Mavenclad (Cladribine Tablets) Data in Multiple Sclerosis Journal Show an Even Greater Treatment Effect in Patients With Highly Active Multiple Sclerosis
Zadavatel: Merck
Mavenclad (Cladribine Tablets) Receives First Approval in Latin America
Zadavatel: Merck
Společnost Merck získala další dva patenty pro technologii CRISPR
Zadavatel: Merck
Singapurský úřad pro duševní vlastnictví má přidělit společnosti Merck patent pro technologii CRISPR
Zadavatel: Merck
Merck Receives Approval (Updated Registration) for Mavenclad (Cladribine Tablets) in Australia
Zadavatel: Merck
Merck's Mavenclad (Cladribine Tablets) Approved for Relapsing-Remitting Multiple Sclerosis in Canada
Zadavatel: Merck
NICE Recommends Mavenclad (Cladribine Tablets) for Highly Active Multiple Sclerosis
Zadavatel: Merck
Společnosti Merck a Samsung BioLogics rozšiřují strategické partnerství
Zadavatel: Merck
Merck Announces Recipients of €1 Million Grant for Multiple Sclerosis Innovation at ECTRIMS 2017
Zadavatel: Merck
New Data at ECTRIMS Highlight Positive Benefit-Risk Profile of Mavenclad in Relapsing Multiple Sclerosis
Zadavatel: Merck
New Report Launched at ECTRIMS 2017 Highlights Unique Impact of MS on Women in Europe
Zadavatel: Merck
Kanadský patentový úřad má přiznat společnosti Merck patentová práva na její technologii CRISPR
Zadavatel: Merck
Společnost Merck přibližuje zákazníky ke komercionalizaci produktů genové terapie
Zadavatel: Merck
Nalezeno zpráv: 41